Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KT-721
- Development stage
- Unknown
- Lead developer
- Kimia Therapeutics
- Modality
- Small Molecules
01
Overview
KT-721 is an investigational, small-molecule oncology drug designed to target pathways critical to tumor cell survival. Discovered using Kimia Therapeutics' proprietary ATLAS (AcTive Learning with Automated Synthesis and Screening) platform, which integrates generative AI with medicinal chemistry, KT-721 is being developed for the treatment of cancer. Under a clinical collaboration agreement, CStone Pharmaceuticals will lead Phase I clinical development of KT-721 in mainland China and Australia, evaluating the drug in biomarker-selected patient populations to establish safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity.
Beyond the preview
Go deeper on KT-721.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KT-721.